SlideShare a Scribd company logo
Partnerships in drug discovery and
development for diseases of the
developing world
Ken Duncan
BioDundee, Dundee
29 May, 2013
2
TOPICS
1. Introduction to the work of the Bill &
Melinda Gates Foundation
2. Drug discovery portfolio
3. Importance of partnerships in TB drug
discovery and development
3
TOPICS
1. Introduction to the work of the Bill &
Melinda Gates Foundation
2. Drug discovery portfolio
3. Importance of partnerships in TB drug
discovery and development
© 2010 Bill & Melinda Gates Foundation |
Our Belief
ALL LIVES
—NO MATTER WHERE THEY ARE BEING LIVED—
HAVE EQUAL VALUE
Our History
Bill and Melinda
read an article
about rotavirus
They officially
create the
foundation
Warren Buffett
decides to
give Berkshire
Hathaway stock
1998 2000 2006 2008
Bill joins Melinda
full-time at the
foundation
$36.4 billion
Asset trust endowment
$26 billion
Grants Since inception
1,100
Employees worldwide
$3.4 billion
2012 grants payments
$31.3 billion
Warren Buffet pledge
Headquarters: Seattle
Offices: London, Washington DC
Country Offices: China, India
Country Representatives:
Ethiopia, South Africa, Nigeria
Reach & Presence
What We Focus On
What are
the areas
of greatest
need?
Where can
we have
the greatest
impact?
United States
Program
Global Health
Program
Global Development
Program
Programs
2011 Grants Paid Summary
For the year ended December 31, 2011. Amount in thousands.
(by Program Area)
Global Health $1,977,507
Global Development $667,780
United States Program $486,917
Operations/Non-Program Grants $48,466
Strategic Media Partnerships $18,379
Policy & Government Affairs $9,117
Integrated Approach for Global Health
VACCINES
VECTOR CONTROL
SANITATION
FAMILY HEALTH
DRUGS
DIAGNOSTICS
How Our Strategies Align
All strategies seek
transformational change.
All strategies rely on partners and
grantees to carry out the work.
All strategies emphasize
technology.
TOPICS
1. Introduction to the work of the Bill &
Melinda Gates Foundation
2. Drug discovery portfolio
3. Importance of partnerships in TB drug
discovery and development
Drug discovery priorities
Malaria Helminths
Diarrheal
Disease
TB
Platforms
Drug discovery priorities
Malaria
Bell et al. Nature Reviews Microbiology 4, S7–S20 (2006)SERCaP
(Single Encounter
Radical Cure and
Prophylaxis)
Target Product Profile
Drug discovery priorities
Helminths
Onchocerciasis: "River Blindness"
Lymphatic Filariasis: "Elephantiasis"
Macrofilaricide
Kill Adult worms
Safe in Loa loa regions
Target Product Profile
Drug discovery priorities
TB
Novel combination
Shorter, safer treatment
Overcome MDR-TB
Target Product Profile
Drug discovery priorities
Diarrheal
Disease
Adapted from The Global Burden of Disease: 2004 Update; WHO
Anti-secretory
Boost ORS effectiveness
Increase ORS compliance
Target Product Profile
Drug discovery priorities
Platforms
Grantees and partners
Target Lead Candidate
Lead
Optimisation
Target
validation
Pre-clinical Clinical
Development
Lead
Identification
Target
identification
Product Development Partnerships
Academia, Institutes
Pharma
Biotech
TOPICS
1. Introduction to the work of the Bill &
Melinda Gates Foundation
2. Drug discovery portfolio
3. Importance of partnerships in TB drug
discovery and development
TB treatment today
6-24 months
Multiple drugs
Isoniazid
Rifampicin
Pyrazinamide
Ethambutol
Complexity: DOTS
Safety, drug-drug interactions
The World needs a
shorter, safer drug
regimen
Bedaquiline, first new TB drug
approved in over 40 years
December 31, 2012
Importance of Partnerships
Target Lead Candidate
Lead
Optimisation
Target
validation
Pre-clinical Clinical
Development
Lead
Identification
Target
identification
TBDA
CPTR
24
CPTR: A new development paradigm
TBDA
Next generation therapy
Goal:
A new first line drug regimen
that works in one month or less
Problem:
Few new drug candidates, little
diversity
Solution:
An integrated cross-industry-
academia discovery partnership
Challenge:
TBDA
The TBDA is a groundbreaking partnership between seven pharmaceutical companies and
six research institutions collaborating on early TB drug discovery
The TB Drug Accelerator
How it works…
Company
Compound
Libraries
Collaborative Discovery Research 5 new preclinical
candidates
2016
1 month regimen
proof of concept
2021
• Hit and Lead Generation
• Target Identification
• Lead Optimization
Research Institutions: Pharmaceutical Companies: With support from:
TBDA
The TBDA is a New Paradigm For Drug Discovery
The TBDA offers a new approach that addresses many of the bottlenecks in the way TB
drugs are currently developed
ONLY THE BEST CANDIDATES ADVANCE
Early
Collaboration
Avoid
Redundancy
Data
Sharing
Maximize
Efficiency
Overcome
Competitive
Barriers
Companies Work
on Each Other’s
Compounds
TBDA
• Partnerships such as the TBDA show how industry and others can work
together in new ways to support global health innovation
• The TBDA model could be applied to other disease areas that lack incentives
for research or require combination drug therapies
The TBDA Offers a Model for
Other Initiatives
EVERY PERSON DESERVES THE
CHANCE TO LIVE A
HEALTHY, PRODUCTIVE LIFE.
All Rights Reserved. Bill & Melinda Gates Foundation is a registered trademark in the United States and other countries.
Learn More
www.GatesFoundation.org
www.ImpatientOptimists.org
BillandMelindaGatesFoundation
@GatesFoundation

More Related Content

What's hot

Microfinance
MicrofinanceMicrofinance
Microfinance
zendeem
 
Philantropic Foundations and Multilateral Aid Institutions like the World Ban...
Philantropic Foundations and Multilateral Aid Institutions like the World Ban...Philantropic Foundations and Multilateral Aid Institutions like the World Ban...
Philantropic Foundations and Multilateral Aid Institutions like the World Ban...
Euforic Services
 
Microfinancing in the Developing World
Microfinancing in the Developing WorldMicrofinancing in the Developing World
Microfinancing in the Developing World
Graeme Lamb
 
Ccih2019 usaid-dianna-lightfoot
Ccih2019 usaid-dianna-lightfootCcih2019 usaid-dianna-lightfoot
Ccih2019 usaid-dianna-lightfoot
Christian Connections for International Health
 
Rotary Continues Funding Fight against Polio Worldwide
Rotary Continues Funding Fight against Polio WorldwideRotary Continues Funding Fight against Polio Worldwide
Rotary Continues Funding Fight against Polio Worldwide
Peter Killcommons
 
Green 2.0 - Danielle Deane
Green 2.0 - Danielle DeaneGreen 2.0 - Danielle Deane
Green 2.0 - Danielle Deane
Sustainable Urban Forests Coalition
 
Asian Development Bank Outlook (ADO) 2019 update
Asian Development Bank Outlook (ADO) 2019 updateAsian Development Bank Outlook (ADO) 2019 update
Asian Development Bank Outlook (ADO) 2019 update
MYO AUNG Myanmar
 
YieldWise: How the World Can Cut Food Waste and Loss by Half
YieldWise: How the World Can Cut Food Waste and Loss by HalfYieldWise: How the World Can Cut Food Waste and Loss by Half
YieldWise: How the World Can Cut Food Waste and Loss by Half
The Rockefeller Foundation
 
How To Volunteer At Hands on Manila
How To Volunteer At Hands on ManilaHow To Volunteer At Hands on Manila
How To Volunteer At Hands on Manila
Mai Mislang
 
This is Africa - Realising Africa's Potential
This is Africa - Realising Africa's PotentialThis is Africa - Realising Africa's Potential
This is Africa - Realising Africa's Potential
The Rockefeller Foundation
 
The Global Agriculture and Food Security Program
The Global Agriculture and Food Security ProgramThe Global Agriculture and Food Security Program
The Global Agriculture and Food Security Program
Francois Stepman
 
A comparision of management system for development cooperation
A comparision of management system for development cooperationA comparision of management system for development cooperation
A comparision of management system for development cooperationबि. बि. राई
 
Key Factors Supporting Small Scale Coastal Fisheries Management
Key Factors Supporting Small Scale Coastal Fisheries ManagementKey Factors Supporting Small Scale Coastal Fisheries Management
Key Factors Supporting Small Scale Coastal Fisheries Management
The Rockefeller Foundation
 
Comparing FISP to Alternative Programs
Comparing FISP to Alternative ProgramsComparing FISP to Alternative Programs
Comparing FISP to Alternative Programs
IFPRIMaSSP
 
Mdg's elp
Mdg's elpMdg's elp
Mdg's elpazyan12
 
Asian Development Bank - Vinay Patidar
Asian Development Bank - Vinay PatidarAsian Development Bank - Vinay Patidar
Asian Development Bank - Vinay Patidar
Vinay Patidar
 
World bank
World bankWorld bank
World bank
Neelam Yadav
 
Care International - Bangladesh
Care International - BangladeshCare International - Bangladesh
Care International - BangladeshJhuma Halder
 

What's hot (20)

Microfinance
MicrofinanceMicrofinance
Microfinance
 
Philantropic Foundations and Multilateral Aid Institutions like the World Ban...
Philantropic Foundations and Multilateral Aid Institutions like the World Ban...Philantropic Foundations and Multilateral Aid Institutions like the World Ban...
Philantropic Foundations and Multilateral Aid Institutions like the World Ban...
 
Microfinancing in the Developing World
Microfinancing in the Developing WorldMicrofinancing in the Developing World
Microfinancing in the Developing World
 
Ccih2019 usaid-dianna-lightfoot
Ccih2019 usaid-dianna-lightfootCcih2019 usaid-dianna-lightfoot
Ccih2019 usaid-dianna-lightfoot
 
Rotary Continues Funding Fight against Polio Worldwide
Rotary Continues Funding Fight against Polio WorldwideRotary Continues Funding Fight against Polio Worldwide
Rotary Continues Funding Fight against Polio Worldwide
 
Livelihood SriLanka
Livelihood SriLankaLivelihood SriLanka
Livelihood SriLanka
 
Green 2.0 - Danielle Deane
Green 2.0 - Danielle DeaneGreen 2.0 - Danielle Deane
Green 2.0 - Danielle Deane
 
Asian Development Bank Outlook (ADO) 2019 update
Asian Development Bank Outlook (ADO) 2019 updateAsian Development Bank Outlook (ADO) 2019 update
Asian Development Bank Outlook (ADO) 2019 update
 
YieldWise: How the World Can Cut Food Waste and Loss by Half
YieldWise: How the World Can Cut Food Waste and Loss by HalfYieldWise: How the World Can Cut Food Waste and Loss by Half
YieldWise: How the World Can Cut Food Waste and Loss by Half
 
How To Volunteer At Hands on Manila
How To Volunteer At Hands on ManilaHow To Volunteer At Hands on Manila
How To Volunteer At Hands on Manila
 
This is Africa - Realising Africa's Potential
This is Africa - Realising Africa's PotentialThis is Africa - Realising Africa's Potential
This is Africa - Realising Africa's Potential
 
The Global Agriculture and Food Security Program
The Global Agriculture and Food Security ProgramThe Global Agriculture and Food Security Program
The Global Agriculture and Food Security Program
 
A comparision of management system for development cooperation
A comparision of management system for development cooperationA comparision of management system for development cooperation
A comparision of management system for development cooperation
 
Key Factors Supporting Small Scale Coastal Fisheries Management
Key Factors Supporting Small Scale Coastal Fisheries ManagementKey Factors Supporting Small Scale Coastal Fisheries Management
Key Factors Supporting Small Scale Coastal Fisheries Management
 
Comparing FISP to Alternative Programs
Comparing FISP to Alternative ProgramsComparing FISP to Alternative Programs
Comparing FISP to Alternative Programs
 
Mdg's elp
Mdg's elpMdg's elp
Mdg's elp
 
Asian Development Bank - Vinay Patidar
Asian Development Bank - Vinay PatidarAsian Development Bank - Vinay Patidar
Asian Development Bank - Vinay Patidar
 
Concept note e
Concept note eConcept note e
Concept note e
 
World bank
World bankWorld bank
World bank
 
Care International - Bangladesh
Care International - BangladeshCare International - Bangladesh
Care International - Bangladesh
 

Viewers also liked

Gates foundation
Gates foundationGates foundation
Gates foundation
Kari900
 
Bill & Melinda Gates Foundation
Bill & Melinda Gates FoundationBill & Melinda Gates Foundation
Bill & Melinda Gates Foundation
Ethan Chong
 
Nick Juleff, Senior Program Officer, Bill & Melinda Gates Foundation
Nick Juleff, Senior Program Officer, Bill & Melinda Gates FoundationNick Juleff, Senior Program Officer, Bill & Melinda Gates Foundation
Nick Juleff, Senior Program Officer, Bill & Melinda Gates Foundation
Kisaco Research
 
William Wade, Professor Oral Microbiology, Barts and The London School of Med...
William Wade, Professor Oral Microbiology, Barts and The London School of Med...William Wade, Professor Oral Microbiology, Barts and The London School of Med...
William Wade, Professor Oral Microbiology, Barts and The London School of Med...
Kisaco Research
 
Bill and melinda gates foundation 1
Bill and melinda gates foundation 1Bill and melinda gates foundation 1
Bill and melinda gates foundation 1
elementalfire
 
Bill and melinda gate foundation
Bill and melinda gate foundationBill and melinda gate foundation
Bill and melinda gate foundationFei Xiong
 
Case Study: SocialCops + Oxfam India
Case Study: SocialCops + Oxfam IndiaCase Study: SocialCops + Oxfam India
Case Study: SocialCops + Oxfam India
SocialCops
 
Case Study: SocialCops + Bill & Melinda Gates Foundation
Case Study: SocialCops + Bill & Melinda Gates FoundationCase Study: SocialCops + Bill & Melinda Gates Foundation
Case Study: SocialCops + Bill & Melinda Gates Foundation
SocialCops
 

Viewers also liked (8)

Gates foundation
Gates foundationGates foundation
Gates foundation
 
Bill & Melinda Gates Foundation
Bill & Melinda Gates FoundationBill & Melinda Gates Foundation
Bill & Melinda Gates Foundation
 
Nick Juleff, Senior Program Officer, Bill & Melinda Gates Foundation
Nick Juleff, Senior Program Officer, Bill & Melinda Gates FoundationNick Juleff, Senior Program Officer, Bill & Melinda Gates Foundation
Nick Juleff, Senior Program Officer, Bill & Melinda Gates Foundation
 
William Wade, Professor Oral Microbiology, Barts and The London School of Med...
William Wade, Professor Oral Microbiology, Barts and The London School of Med...William Wade, Professor Oral Microbiology, Barts and The London School of Med...
William Wade, Professor Oral Microbiology, Barts and The London School of Med...
 
Bill and melinda gates foundation 1
Bill and melinda gates foundation 1Bill and melinda gates foundation 1
Bill and melinda gates foundation 1
 
Bill and melinda gate foundation
Bill and melinda gate foundationBill and melinda gate foundation
Bill and melinda gate foundation
 
Case Study: SocialCops + Oxfam India
Case Study: SocialCops + Oxfam IndiaCase Study: SocialCops + Oxfam India
Case Study: SocialCops + Oxfam India
 
Case Study: SocialCops + Bill & Melinda Gates Foundation
Case Study: SocialCops + Bill & Melinda Gates FoundationCase Study: SocialCops + Bill & Melinda Gates Foundation
Case Study: SocialCops + Bill & Melinda Gates Foundation
 

Similar to Bill & Melinda Gates foundation - Ken Duncan

Working in Global HealthChapter 18Chapter 18 Working i
Working in Global HealthChapter  18Chapter 18 Working iWorking in Global HealthChapter  18Chapter 18 Working i
Working in Global HealthChapter 18Chapter 18 Working i
rosacrosdale
 
Oct 25 CAPHC Breakfast Symposium - Sponsored by Alexion - CORD
Oct 25   CAPHC Breakfast Symposium - Sponsored by Alexion - CORDOct 25   CAPHC Breakfast Symposium - Sponsored by Alexion - CORD
Oct 25 CAPHC Breakfast Symposium - Sponsored by Alexion - CORD
Glenna Gosewich
 
Oct 25 CAPHC Breakfast Symposium - Sponsored by Alexion - CORD
Oct 25 CAPHC Breakfast Symposium - Sponsored by Alexion - CORDOct 25 CAPHC Breakfast Symposium - Sponsored by Alexion - CORD
Oct 25 CAPHC Breakfast Symposium - Sponsored by Alexion - CORD
Canadian Association of Paediatric Health Centres
 
Beyond borders
Beyond bordersBeyond borders
Beyond borders
thegoodlife10025
 
Tomorrow’s Lab Today: Understanding the challenges facing diagnostic testing ...
Tomorrow’s Lab Today: Understanding the challenges facing diagnostic testing ...Tomorrow’s Lab Today: Understanding the challenges facing diagnostic testing ...
Tomorrow’s Lab Today: Understanding the challenges facing diagnostic testing ...
Serene Touma
 
10 healthcare players aiming beyond health equality to conquer health equity
10 healthcare players aiming beyond health equality to conquer health equity10 healthcare players aiming beyond health equality to conquer health equity
10 healthcare players aiming beyond health equality to conquer health equity
Insights10
 
DIA Global Forum: Are Clinical Trials Ready to Embrace the IoE?
DIA Global Forum: Are Clinical Trials Ready to Embrace the IoE?DIA Global Forum: Are Clinical Trials Ready to Embrace the IoE?
DIA Global Forum: Are Clinical Trials Ready to Embrace the IoE?
Jackie Brusch
 
Tomorrow’s Lab Today: Focus areas for medical biology and diagnostic testing ...
Tomorrow’s Lab Today: Focus areas for medical biology and diagnostic testing ...Tomorrow’s Lab Today: Focus areas for medical biology and diagnostic testing ...
Tomorrow’s Lab Today: Focus areas for medical biology and diagnostic testing ...
Serene Touma
 
Roche_Genentech_Company_Presentation_2022.pdf
Roche_Genentech_Company_Presentation_2022.pdfRoche_Genentech_Company_Presentation_2022.pdf
Roche_Genentech_Company_Presentation_2022.pdf
MOHAMMED YASER HUSSAIN
 
Recap - Patient Engagement: The Future of Healthcare Communications Summit
Recap - Patient Engagement: The Future of Healthcare Communications SummitRecap - Patient Engagement: The Future of Healthcare Communications Summit
Recap - Patient Engagement: The Future of Healthcare Communications Summit
prnewswire
 
Changing the Medical Research Paradigm
Changing the Medical Research ParadigmChanging the Medical Research Paradigm
Changing the Medical Research Paradigm
RAWE_INC
 
Grassroots basics
Grassroots basicsGrassroots basics
Grassroots basicsShcl1438
 
Introduction to HealthXL
Introduction to HealthXL Introduction to HealthXL
Introduction to HealthXL
HealthXL Global
 
2012 EY Biotech Report
2012 EY Biotech Report2012 EY Biotech Report
2012 EY Biotech ReportGautam Jaggi
 
Patient Advocacy Groups Benefits To Oncology Commercialization [www.BiomedwoR...
Patient Advocacy Groups Benefits To Oncology Commercialization [www.BiomedwoR...Patient Advocacy Groups Benefits To Oncology Commercialization [www.BiomedwoR...
Patient Advocacy Groups Benefits To Oncology Commercialization [www.BiomedwoR...
Michael W. Young
 
Health 2.0 Is Here Now What Opma Mtg May 7 2009 Slide Share
Health 2.0 Is Here Now What   Opma Mtg   May 7 2009   Slide ShareHealth 2.0 Is Here Now What   Opma Mtg   May 7 2009   Slide Share
Health 2.0 Is Here Now What Opma Mtg May 7 2009 Slide Share
Nat Bourre
 
Is Pharma Ready
Is Pharma ReadyIs Pharma Ready
Is Pharma Ready
Rob Lindeman
 
Working with the FDA
Working with the FDAWorking with the FDA
Chelation partners 2021 Collision Conference pitch
Chelation partners 2021 Collision Conference pitchChelation partners 2021 Collision Conference pitch
Chelation partners 2021 Collision Conference pitch
Michael Weickert, Ph.D
 
(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREAD
(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREAD(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREAD
(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREADPinky Fadullon
 

Similar to Bill & Melinda Gates foundation - Ken Duncan (20)

Working in Global HealthChapter 18Chapter 18 Working i
Working in Global HealthChapter  18Chapter 18 Working iWorking in Global HealthChapter  18Chapter 18 Working i
Working in Global HealthChapter 18Chapter 18 Working i
 
Oct 25 CAPHC Breakfast Symposium - Sponsored by Alexion - CORD
Oct 25   CAPHC Breakfast Symposium - Sponsored by Alexion - CORDOct 25   CAPHC Breakfast Symposium - Sponsored by Alexion - CORD
Oct 25 CAPHC Breakfast Symposium - Sponsored by Alexion - CORD
 
Oct 25 CAPHC Breakfast Symposium - Sponsored by Alexion - CORD
Oct 25 CAPHC Breakfast Symposium - Sponsored by Alexion - CORDOct 25 CAPHC Breakfast Symposium - Sponsored by Alexion - CORD
Oct 25 CAPHC Breakfast Symposium - Sponsored by Alexion - CORD
 
Beyond borders
Beyond bordersBeyond borders
Beyond borders
 
Tomorrow’s Lab Today: Understanding the challenges facing diagnostic testing ...
Tomorrow’s Lab Today: Understanding the challenges facing diagnostic testing ...Tomorrow’s Lab Today: Understanding the challenges facing diagnostic testing ...
Tomorrow’s Lab Today: Understanding the challenges facing diagnostic testing ...
 
10 healthcare players aiming beyond health equality to conquer health equity
10 healthcare players aiming beyond health equality to conquer health equity10 healthcare players aiming beyond health equality to conquer health equity
10 healthcare players aiming beyond health equality to conquer health equity
 
DIA Global Forum: Are Clinical Trials Ready to Embrace the IoE?
DIA Global Forum: Are Clinical Trials Ready to Embrace the IoE?DIA Global Forum: Are Clinical Trials Ready to Embrace the IoE?
DIA Global Forum: Are Clinical Trials Ready to Embrace the IoE?
 
Tomorrow’s Lab Today: Focus areas for medical biology and diagnostic testing ...
Tomorrow’s Lab Today: Focus areas for medical biology and diagnostic testing ...Tomorrow’s Lab Today: Focus areas for medical biology and diagnostic testing ...
Tomorrow’s Lab Today: Focus areas for medical biology and diagnostic testing ...
 
Roche_Genentech_Company_Presentation_2022.pdf
Roche_Genentech_Company_Presentation_2022.pdfRoche_Genentech_Company_Presentation_2022.pdf
Roche_Genentech_Company_Presentation_2022.pdf
 
Recap - Patient Engagement: The Future of Healthcare Communications Summit
Recap - Patient Engagement: The Future of Healthcare Communications SummitRecap - Patient Engagement: The Future of Healthcare Communications Summit
Recap - Patient Engagement: The Future of Healthcare Communications Summit
 
Changing the Medical Research Paradigm
Changing the Medical Research ParadigmChanging the Medical Research Paradigm
Changing the Medical Research Paradigm
 
Grassroots basics
Grassroots basicsGrassroots basics
Grassroots basics
 
Introduction to HealthXL
Introduction to HealthXL Introduction to HealthXL
Introduction to HealthXL
 
2012 EY Biotech Report
2012 EY Biotech Report2012 EY Biotech Report
2012 EY Biotech Report
 
Patient Advocacy Groups Benefits To Oncology Commercialization [www.BiomedwoR...
Patient Advocacy Groups Benefits To Oncology Commercialization [www.BiomedwoR...Patient Advocacy Groups Benefits To Oncology Commercialization [www.BiomedwoR...
Patient Advocacy Groups Benefits To Oncology Commercialization [www.BiomedwoR...
 
Health 2.0 Is Here Now What Opma Mtg May 7 2009 Slide Share
Health 2.0 Is Here Now What   Opma Mtg   May 7 2009   Slide ShareHealth 2.0 Is Here Now What   Opma Mtg   May 7 2009   Slide Share
Health 2.0 Is Here Now What Opma Mtg May 7 2009 Slide Share
 
Is Pharma Ready
Is Pharma ReadyIs Pharma Ready
Is Pharma Ready
 
Working with the FDA
Working with the FDAWorking with the FDA
Working with the FDA
 
Chelation partners 2021 Collision Conference pitch
Chelation partners 2021 Collision Conference pitchChelation partners 2021 Collision Conference pitch
Chelation partners 2021 Collision Conference pitch
 
(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREAD
(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREAD(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREAD
(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREAD
 

Recently uploaded

Normal Labour/ Stages of Labour/ Mechanism of Labour
Normal Labour/ Stages of Labour/ Mechanism of LabourNormal Labour/ Stages of Labour/ Mechanism of Labour
Normal Labour/ Stages of Labour/ Mechanism of Labour
Wasim Ak
 
Unit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdfUnit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdf
Thiyagu K
 
Landownership in the Philippines under the Americans-2-pptx.pptx
Landownership in the Philippines under the Americans-2-pptx.pptxLandownership in the Philippines under the Americans-2-pptx.pptx
Landownership in the Philippines under the Americans-2-pptx.pptx
JezreelCabil2
 
The Diamonds of 2023-2024 in the IGRA collection
The Diamonds of 2023-2024 in the IGRA collectionThe Diamonds of 2023-2024 in the IGRA collection
The Diamonds of 2023-2024 in the IGRA collection
Israel Genealogy Research Association
 
The simplified electron and muon model, Oscillating Spacetime: The Foundation...
The simplified electron and muon model, Oscillating Spacetime: The Foundation...The simplified electron and muon model, Oscillating Spacetime: The Foundation...
The simplified electron and muon model, Oscillating Spacetime: The Foundation...
RitikBhardwaj56
 
S1-Introduction-Biopesticides in ICM.pptx
S1-Introduction-Biopesticides in ICM.pptxS1-Introduction-Biopesticides in ICM.pptx
S1-Introduction-Biopesticides in ICM.pptx
tarandeep35
 
Aficamten in HCM (SEQUOIA HCM TRIAL 2024)
Aficamten in HCM (SEQUOIA HCM TRIAL 2024)Aficamten in HCM (SEQUOIA HCM TRIAL 2024)
Aficamten in HCM (SEQUOIA HCM TRIAL 2024)
Ashish Kohli
 
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
MysoreMuleSoftMeetup
 
Acetabularia Information For Class 9 .docx
Acetabularia Information For Class 9  .docxAcetabularia Information For Class 9  .docx
Acetabularia Information For Class 9 .docx
vaibhavrinwa19
 
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
Nguyen Thanh Tu Collection
 
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
Levi Shapiro
 
RPMS TEMPLATE FOR SCHOOL YEAR 2023-2024 FOR TEACHER 1 TO TEACHER 3
RPMS TEMPLATE FOR SCHOOL YEAR 2023-2024 FOR TEACHER 1 TO TEACHER 3RPMS TEMPLATE FOR SCHOOL YEAR 2023-2024 FOR TEACHER 1 TO TEACHER 3
RPMS TEMPLATE FOR SCHOOL YEAR 2023-2024 FOR TEACHER 1 TO TEACHER 3
IreneSebastianRueco1
 
A Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in EducationA Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in Education
Peter Windle
 
Thesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.pptThesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.ppt
EverAndrsGuerraGuerr
 
Digital Artefact 1 - Tiny Home Environmental Design
Digital Artefact 1 - Tiny Home Environmental DesignDigital Artefact 1 - Tiny Home Environmental Design
Digital Artefact 1 - Tiny Home Environmental Design
amberjdewit93
 
South African Journal of Science: Writing with integrity workshop (2024)
South African Journal of Science: Writing with integrity workshop (2024)South African Journal of Science: Writing with integrity workshop (2024)
South African Journal of Science: Writing with integrity workshop (2024)
Academy of Science of South Africa
 
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
EugeneSaldivar
 
DRUGS AND ITS classification slide share
DRUGS AND ITS classification slide shareDRUGS AND ITS classification slide share
DRUGS AND ITS classification slide share
taiba qazi
 
Chapter 4 - Islamic Financial Institutions in Malaysia.pptx
Chapter 4 - Islamic Financial Institutions in Malaysia.pptxChapter 4 - Islamic Financial Institutions in Malaysia.pptx
Chapter 4 - Islamic Financial Institutions in Malaysia.pptx
Mohd Adib Abd Muin, Senior Lecturer at Universiti Utara Malaysia
 
Advantages and Disadvantages of CMS from an SEO Perspective
Advantages and Disadvantages of CMS from an SEO PerspectiveAdvantages and Disadvantages of CMS from an SEO Perspective
Advantages and Disadvantages of CMS from an SEO Perspective
Krisztián Száraz
 

Recently uploaded (20)

Normal Labour/ Stages of Labour/ Mechanism of Labour
Normal Labour/ Stages of Labour/ Mechanism of LabourNormal Labour/ Stages of Labour/ Mechanism of Labour
Normal Labour/ Stages of Labour/ Mechanism of Labour
 
Unit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdfUnit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdf
 
Landownership in the Philippines under the Americans-2-pptx.pptx
Landownership in the Philippines under the Americans-2-pptx.pptxLandownership in the Philippines under the Americans-2-pptx.pptx
Landownership in the Philippines under the Americans-2-pptx.pptx
 
The Diamonds of 2023-2024 in the IGRA collection
The Diamonds of 2023-2024 in the IGRA collectionThe Diamonds of 2023-2024 in the IGRA collection
The Diamonds of 2023-2024 in the IGRA collection
 
The simplified electron and muon model, Oscillating Spacetime: The Foundation...
The simplified electron and muon model, Oscillating Spacetime: The Foundation...The simplified electron and muon model, Oscillating Spacetime: The Foundation...
The simplified electron and muon model, Oscillating Spacetime: The Foundation...
 
S1-Introduction-Biopesticides in ICM.pptx
S1-Introduction-Biopesticides in ICM.pptxS1-Introduction-Biopesticides in ICM.pptx
S1-Introduction-Biopesticides in ICM.pptx
 
Aficamten in HCM (SEQUOIA HCM TRIAL 2024)
Aficamten in HCM (SEQUOIA HCM TRIAL 2024)Aficamten in HCM (SEQUOIA HCM TRIAL 2024)
Aficamten in HCM (SEQUOIA HCM TRIAL 2024)
 
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
 
Acetabularia Information For Class 9 .docx
Acetabularia Information For Class 9  .docxAcetabularia Information For Class 9  .docx
Acetabularia Information For Class 9 .docx
 
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
 
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
 
RPMS TEMPLATE FOR SCHOOL YEAR 2023-2024 FOR TEACHER 1 TO TEACHER 3
RPMS TEMPLATE FOR SCHOOL YEAR 2023-2024 FOR TEACHER 1 TO TEACHER 3RPMS TEMPLATE FOR SCHOOL YEAR 2023-2024 FOR TEACHER 1 TO TEACHER 3
RPMS TEMPLATE FOR SCHOOL YEAR 2023-2024 FOR TEACHER 1 TO TEACHER 3
 
A Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in EducationA Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in Education
 
Thesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.pptThesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.ppt
 
Digital Artefact 1 - Tiny Home Environmental Design
Digital Artefact 1 - Tiny Home Environmental DesignDigital Artefact 1 - Tiny Home Environmental Design
Digital Artefact 1 - Tiny Home Environmental Design
 
South African Journal of Science: Writing with integrity workshop (2024)
South African Journal of Science: Writing with integrity workshop (2024)South African Journal of Science: Writing with integrity workshop (2024)
South African Journal of Science: Writing with integrity workshop (2024)
 
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
 
DRUGS AND ITS classification slide share
DRUGS AND ITS classification slide shareDRUGS AND ITS classification slide share
DRUGS AND ITS classification slide share
 
Chapter 4 - Islamic Financial Institutions in Malaysia.pptx
Chapter 4 - Islamic Financial Institutions in Malaysia.pptxChapter 4 - Islamic Financial Institutions in Malaysia.pptx
Chapter 4 - Islamic Financial Institutions in Malaysia.pptx
 
Advantages and Disadvantages of CMS from an SEO Perspective
Advantages and Disadvantages of CMS from an SEO PerspectiveAdvantages and Disadvantages of CMS from an SEO Perspective
Advantages and Disadvantages of CMS from an SEO Perspective
 

Bill & Melinda Gates foundation - Ken Duncan

  • 1. Partnerships in drug discovery and development for diseases of the developing world Ken Duncan BioDundee, Dundee 29 May, 2013
  • 2. 2 TOPICS 1. Introduction to the work of the Bill & Melinda Gates Foundation 2. Drug discovery portfolio 3. Importance of partnerships in TB drug discovery and development
  • 3. 3 TOPICS 1. Introduction to the work of the Bill & Melinda Gates Foundation 2. Drug discovery portfolio 3. Importance of partnerships in TB drug discovery and development
  • 4. © 2010 Bill & Melinda Gates Foundation | Our Belief ALL LIVES —NO MATTER WHERE THEY ARE BEING LIVED— HAVE EQUAL VALUE
  • 5. Our History Bill and Melinda read an article about rotavirus They officially create the foundation Warren Buffett decides to give Berkshire Hathaway stock 1998 2000 2006 2008 Bill joins Melinda full-time at the foundation
  • 6. $36.4 billion Asset trust endowment $26 billion Grants Since inception 1,100 Employees worldwide $3.4 billion 2012 grants payments $31.3 billion Warren Buffet pledge Headquarters: Seattle Offices: London, Washington DC Country Offices: China, India Country Representatives: Ethiopia, South Africa, Nigeria Reach & Presence
  • 7. What We Focus On What are the areas of greatest need? Where can we have the greatest impact?
  • 9. 2011 Grants Paid Summary For the year ended December 31, 2011. Amount in thousands. (by Program Area) Global Health $1,977,507 Global Development $667,780 United States Program $486,917 Operations/Non-Program Grants $48,466 Strategic Media Partnerships $18,379 Policy & Government Affairs $9,117
  • 10. Integrated Approach for Global Health VACCINES VECTOR CONTROL SANITATION FAMILY HEALTH DRUGS DIAGNOSTICS
  • 11. How Our Strategies Align All strategies seek transformational change. All strategies rely on partners and grantees to carry out the work. All strategies emphasize technology.
  • 12. TOPICS 1. Introduction to the work of the Bill & Melinda Gates Foundation 2. Drug discovery portfolio 3. Importance of partnerships in TB drug discovery and development
  • 13. Drug discovery priorities Malaria Helminths Diarrheal Disease TB Platforms
  • 14. Drug discovery priorities Malaria Bell et al. Nature Reviews Microbiology 4, S7–S20 (2006)SERCaP (Single Encounter Radical Cure and Prophylaxis) Target Product Profile
  • 15. Drug discovery priorities Helminths Onchocerciasis: "River Blindness" Lymphatic Filariasis: "Elephantiasis" Macrofilaricide Kill Adult worms Safe in Loa loa regions Target Product Profile
  • 16. Drug discovery priorities TB Novel combination Shorter, safer treatment Overcome MDR-TB Target Product Profile
  • 17. Drug discovery priorities Diarrheal Disease Adapted from The Global Burden of Disease: 2004 Update; WHO Anti-secretory Boost ORS effectiveness Increase ORS compliance Target Product Profile
  • 19. Grantees and partners Target Lead Candidate Lead Optimisation Target validation Pre-clinical Clinical Development Lead Identification Target identification Product Development Partnerships Academia, Institutes Pharma Biotech
  • 20. TOPICS 1. Introduction to the work of the Bill & Melinda Gates Foundation 2. Drug discovery portfolio 3. Importance of partnerships in TB drug discovery and development
  • 21. TB treatment today 6-24 months Multiple drugs Isoniazid Rifampicin Pyrazinamide Ethambutol Complexity: DOTS Safety, drug-drug interactions The World needs a shorter, safer drug regimen
  • 22. Bedaquiline, first new TB drug approved in over 40 years December 31, 2012
  • 23. Importance of Partnerships Target Lead Candidate Lead Optimisation Target validation Pre-clinical Clinical Development Lead Identification Target identification TBDA CPTR
  • 24. 24
  • 25. CPTR: A new development paradigm
  • 26. TBDA Next generation therapy Goal: A new first line drug regimen that works in one month or less Problem: Few new drug candidates, little diversity Solution: An integrated cross-industry- academia discovery partnership Challenge:
  • 27. TBDA The TBDA is a groundbreaking partnership between seven pharmaceutical companies and six research institutions collaborating on early TB drug discovery The TB Drug Accelerator How it works… Company Compound Libraries Collaborative Discovery Research 5 new preclinical candidates 2016 1 month regimen proof of concept 2021 • Hit and Lead Generation • Target Identification • Lead Optimization Research Institutions: Pharmaceutical Companies: With support from:
  • 28. TBDA The TBDA is a New Paradigm For Drug Discovery The TBDA offers a new approach that addresses many of the bottlenecks in the way TB drugs are currently developed ONLY THE BEST CANDIDATES ADVANCE Early Collaboration Avoid Redundancy Data Sharing Maximize Efficiency Overcome Competitive Barriers Companies Work on Each Other’s Compounds
  • 29. TBDA • Partnerships such as the TBDA show how industry and others can work together in new ways to support global health innovation • The TBDA model could be applied to other disease areas that lack incentives for research or require combination drug therapies The TBDA Offers a Model for Other Initiatives
  • 30. EVERY PERSON DESERVES THE CHANCE TO LIVE A HEALTHY, PRODUCTIVE LIFE.
  • 31. All Rights Reserved. Bill & Melinda Gates Foundation is a registered trademark in the United States and other countries. Learn More www.GatesFoundation.org www.ImpatientOptimists.org BillandMelindaGatesFoundation @GatesFoundation

Editor's Notes

  1. Broken up talk into three sections
  2. Broken up talk into three sections
  3. The Bill & Melinda Gates Foundation is a private foundation. The family decided to invest their resource to make their beliefs a reality , ALL LIVES NO MATTER WHERE THEY ARE BEING LIVED HAVE EQUAL VALUE. TRANSITION - This belief is the building blocks of our work.
  4. More than a decade ago, Bill and Melinda read a newspaper article about the millions of children dying each year in poor countries from diseases that most people in the United States don’t have to worry about. One disease in particular—rotavirus—caught their attention. It was killing half a million children a year. They’d never even heard of rotavirus. They thought that that figure might be a typo. In 2006, Warren Buffett surprised them with a pledge of most of his shares in Berkshire Hathaway, doubling the foundation’s annual grantmaking and potential impact. In 2008,Bill made his transition from Microsoft, joining Melinda in a full-time role at the foundation. The foundation was established on Bill’s and Melinda’s passion to address some of the inequities in the world, with the premise that all lives, no matter where they are being lived, have equal value
  5. Total 2012 Grant Payments: $3.4 billion (figure includes other direct charitable contributions of $234 million)Asset Trust Endowment: $36.4 billion (as of December, 31, 2012)Remaining Warren Buffet Pledge: $31.3 billion
  6. To be successful, we have to focus on a set of problems. To do that, we ask two key questions.
  7. Work divided into 3 main areasUS programs: education,libraries, and Pacific NWGlobal Development:Agricultural Development; Financial Services for the Poor; Water, Sanitation & Hygiene; Special InitiativesGlobal Health:harnesses advances in science and technology to save lives in poor countriesfocus on the health problems that have a major impact in developing countries but get too little attention and funding. Where proven tools exist, we support sustainable ways to improve their delivery. Where they don’t, we invest in research and development of new interventions, such as vaccines, drugs, and diagnostics. we allocate about half of our resources to our work in global health, a quarter to our work in the United States, and another quarter to our work in global development
  8. To give you a sense of our scale and how we allocate these funds:Our endowment (as of Dec. 31, 2012) is $36.4 billion. We now employee over 1,100 people, and each year we give out about $3.4 billion in grants as of last year.This chart illustrates where our grants were made in 2011. You can see that Global Health received about 63 percent of our grantee funds with investments of more than $1.98 billion. Global Development grantees received $668 million while U.S. Program grantees received $487 million—about 21 percent and 16 percent of total program-related grants, respectively. While we are the largest charitable foundation in the world, we know that our money is a drop in the bucket compared to what is needed to solve these problems. For example, California’s public education annual budget is $57 billion annually. So, we see our funding as catalytic; we leverage our funds to bring even more funding and attention to issues.Recently, Bill and Melinda accelerated the timeline to sunset the foundation. Formerly 50 years, all resources will now be spent within 20 years of their deaths.
  9. Summary of Changes with the Global ProgramsThat’s why we decided to create a new Global Programs structure to encourage a more integrated approach to our work. Program teams focused on areas ranging from agricultural development to vaccines are now working together more closely on the discovery and delivery of health and development innovations that will meet the many needs of the people we serve.Our goal is to maximize discovery and delivery in global health and development, as well as increase the relevance and impact of our in-country work. Working across Global Programs and engaging grantees and partners alike will increase our local-country insight—which ultimately helps us achieve greater results in the countries where we work and where the most intensive need exists.Integrated ApproachOur new Global Programs structure aims to meet the many needs of the people we serve:Agricultural Development - Helping poor farm families to grow and sell more food reduces hunger and poverty.Family Planning - Family planning can significantly improve the health and welfare of women and their families.Nutrition - Proper nutrition during pregnancy and in early childhood improves children's health and the quality of their lives for years to come.Malaria - Access to drugs and tools to prevent and treat malaria have saved and improved the lives of millions of families around the world.Vaccines - Vaccines work to save and improve lives and protect children for a lifetime.Sanitation - Improved sanitation increases productivity, reduces healthcare costs, and prevents illness, disability, and early death.
  10. All of our strategies seek enduring, transformational change in people’s lives by discovering tools and approaches that can achieve results on a broad scale.All of our strategies rely on partners and grantees to carry out the work in the field.All of our strategies make use of technology to advance our work—whether it’s online learning tools that help students progress at their own pace, GPS mapping technology to help vaccination teams in the field, or new contraceptive technologies that are cheaper and easier for women to use.
  11. Broken up talk into three sections
  12. Broken up talk into three sections
  13. Current TB regimens drive down bacterial levels quickly, but require months of treatment to rid the body of all TB……The only way to overcome this persistence is through ashorter, more effective regimen
  14. Bill and Melinda Gates started the foundation because they believe every person should have the chance to live a healthy and productive life. This belief underlies all of the foundation’s work to reduce hunger, poverty, and disease around the globe.